keyword
MENU ▼
Read by QxMD icon Read
search

adjuvant treatment breast cancer

keyword
https://www.readbyqxmd.com/read/28528979/sensitization-of-breast-cancer-cells-to-paclitaxel-by-dichloroacetate-through-inhibiting-autophagy
#1
Minghao Wang, Cuiwei Liao, Ying Hu, Wenqin Pan, Jun Jiang
Chemotherapy is still the main adjuvant strategy in the treatment of cancer, however, chemoresistance is also frequently encountered. Autophagy inhibition has been widely accepted as a promising therapeutic strategy in cancer, while the lack of effective and specific autophagy inhibitors hinders its application. Here we found that dichloroacetate (DCA), a small molecule compound, could significantly inhibit the autophagy induced by Doxorubicin in breast cancer cells. And DCA markedly enhances Doxorubicin-induced breast cancer cell death and anti-proliferation in vitro...
May 18, 2017: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/28528451/influence-of-comorbidity-on-chemotherapy-use-for-early-breast-cancer-systematic-review-and-meta-analysis
#2
REVIEW
Melissa J Edwards, Ian D Campbell, Ross A Lawrenson, Marion J Kuper-Hommel
PURPOSE: Patients with early breast cancer and coexistent comorbidities generally experience worse prognosis which may be in part related to inferior treatment. Randomised data on chemotherapy use and tolerance in comorbid patients are limited. We aimed to review the available literature regarding the use of chemotherapy in such patients. METHODS: A systematic search of databases was performed for English-language articles evaluating the impact of comorbidity on chemotherapy use for early breast cancer...
May 20, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28527420/factors-predictive-of-locoregional-recurrence-following-neoadjuvant-chemotherapy-in-patients-with-large-operable-or-locally-advanced-breast-cancer-an-analysis-of-the-eortc-10994-big-1-00-study
#3
Pauline Gillon, Nathan Touati, Christel Breton-Callu, Leen Slaets, David Cameron, Hervé Bonnefoi
PURPOSE: Identification of clinicopathological factors predicting for a locoregional recurrence (LRR) after neoadjuvant chemotherapy (NAC) could help to decide on the optimal locoregional radiotherapy. The objective of this trial is to identify those factors in the context of a phase III trial (European Organisation for Research and Treatment of Cancer 10994). METHODS: Patients received NAC followed by surgery with or without radiotherapy. Radiotherapy was administered according to pre-specified guidelines...
May 17, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28526959/adjuvant-tamoxifen-but-not-aromatase-inhibitor-therapy-decreases-serum-levels-of-the-wnt-inhibitor-dickkopf-1-while-not-affecting-sclerostin-in-breast-cancer-patients
#4
Andy Göbel, Jan D Kuhlmann, Theresa Link, Pauline Wimberger, Andrew J Browne, Martina Rauner, Lorenz C Hofbauer, Tilman D Rachner
PURPOSE: Endocrine therapies, including tamoxifen or aromatase inhibitors, are indispensable for the treatment of patients with estrogen receptor (ER)- and/or progesterone-positive breast cancer. Whereas tamoxifen displays partial ER agonistic effects in bone, aromatase inhibitors increase bone resorption and fracture risk. The Wnt inhibitors dickkopf-1 (DKK-1) and sclerostin negatively impact bone formation and are considered targets for the treatment of bone disorders. However, the effect of endocrine therapies on serum DKK-1 and sclerostin levels in patients with primary breast cancer remains elusive...
May 19, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28516441/decision-making-in-the-surgical-management-of-invasive-breast-cancer-part-2-expanded-applications-for-breast-conserving-surgery
#5
REVIEW
Lisa A Newman
Treatment of early-stage invasive breast cancer with breast-conserving surgery plus radiation therapy (RT) yields overall survival outcomes equivalent to those achieved with mastectomy. Further, breast-conserving surgery is endorsed by the National Comprehensive Cancer Network as being supported by the highest-level, category 1 evidence. Advances in pathologic evaluation, management of multiple tumors, oncoplastic lumpectomy techniques, neoadjuvant chemotherapy, and hypofractionated RT can expand the pool of patients eligible for breast-conserving surgery...
May 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28515242/new-approaches-to-endocrine-therapy-for-breast-cancer
#6
William J Gradishar
The management of advanced hormone receptor-positive disease has evolved with the emergence of CDK4/6 inhibitors. Improvements in progression-free survival of approximately 10 months were noted in pivotal trials of palbociclib. Strong efficacy was also seen with ribociclib, which was recently approved by the FDA. In the adjuvant treatment setting of hormone receptor-positive disease, an important issue for consideration is the duration of endocrine therapy.
May 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28515111/racial%C3%A2-differences-in-adjuvant-endocrine-therapy-use-and-discontinuation-in-association-with-mortality-among-medicare-breast-cancer-patients-by-receptor-status
#7
Albert J Farias, Xianglin L Du
BACKGROUND: There are racial disparities in breast cancer mortality. Our purpose was to determine whether racial/ethnic differences in use and discontinuation of AET differed by hormone receptor status and whether discontinuation was associated with mortality. METHODS: We conducted a retrospective cohort study with SEER/Medicare dataset of women age 65 years or older diagnosed with stage I-III breast cancer in Medicare Part-D from 2007-2009, stratified by hormone receptor status...
May 17, 2017: Cancer Epidemiology, Biomarkers & Prevention
https://www.readbyqxmd.com/read/28510222/primary-ectopic-breast-cancer-of-the-vulva-treated-with-local-excision-of-the-vulva-and-sentinel-lymph-node-biopsy-a-case-report
#8
Takayuki Ishigaki, Yasuo Toriumi, Ryouko Nosaka, Rei Kudou, Yoshimi Imawari, Makiko Kamio, Hiroko Nogi, Hisashi Shioya, Hiroshi Takeyama
Primary breast cancer fairly infrequently occurs in ectopic breast tissue, and primary ectopic breast cancer of the vulva is particularly rare. Only 26 cases have been published in the English-language literature, and there has been no report of primary breast carcinoma of the vulva in Japan. We report a rare case of primary ectopic breast cancer of the vulva that was treated with local excision of the vulva and sentinel lymph node biopsy (SLNB). The patient was a 72-year-old woman who had noticed a right vulvar tumor 10 years earlier...
December 2017: Surgical Case Reports
https://www.readbyqxmd.com/read/28508834/a-dosimetric-analysis-of-cardiac-dose-with-or-without-active-breath-coordinator-moderate-deep-inspiratory-breath-hold-in-left-sided-breast-cancer-radiotherapy
#9
Beena Kunheri, Sanketh Kotne, Sneha S Nair, Dinesh Makuny
BACKGROUND AND AIM: Cardiac toxicity is a major concern for left breast tangential field irradiation. The left ventricle and left anterior descending (LAD) artery are suggested to be radiosensitive and radiation to these structures leads to late lethal cardiotoxicity. Moderate deep inspiration breath hold (mDIBH) during radiation treatment delivery helps in reducing the cardiac dose. This study compares dosimetric parameters of heart with and without active breath coordinator (ABC) mDIBH during tangential field breast cancer radiation...
January 2017: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/28508764/current-incidence-of-different-morphological-types-of-malignant-metastases-to-the-spine-based-on-magnetic-resonance-imaging
#10
Grzegorz Guzik
BACKGROUND: Malignant tumours particularly often metastasise to the spine, causing considerable pain and limiting the patient's physical function. Standard therapy consists in surgical treatment with adjuvant radiotherapy. The qualification for surgery is a multifaceted process and detailed analysis of the morphology of the metastasis is a key factor. Numerous types of classification of metastatic lesions exist, among which the Tomita system, based on MRI findings, appears to be the most practical...
April 12, 2017: Ortopedia, Traumatologia, Rehabilitacja
https://www.readbyqxmd.com/read/28508185/titan-phase-iii-study-of-doxorubicin-cyclophosphamide-followed-by-ixabepilone-or-paclitaxel-in-early-stage-triple-negative-breast-cancer
#11
Denise A Yardley, Edward R Arrowsmith, Brooke R Daniel, Janice Eakle, Adam Brufsky, David R Drosick, Fred Kudrik, Linda D Bosserman, Mark R Keaton, Sharon A Goble, Jeffrey A Bubis, Victor M Priego, Kelly Pendergrass, Yvonne Manalo, Martin Bury, Donald S Gravenor, Gladys I Rodriguez, Roger C Inhorn, Robyn R Young, William N Harwin, Caryn Silver, John D Hainsworth, Howard A Burris
PURPOSE: Ixabepilone is a microtubule stabilizer with activity in taxane-refractory metastatic breast cancer and low susceptibility to taxane-resistance mechanisms including multidrug-resistant phenotypes and high β-III tubulin expression. Since these resistance mechanisms are common in triple-negative breast cancer (TNBC), ixabepilone may have particular advantages in this patient population. This study evaluated the substitution of ixabepilone for paclitaxel following doxorubicin/cyclophosphamide (AC) in the adjuvant treatment of early-stage TNBC...
May 15, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28507871/mammary-malignant-ulcer-after-radiotherapy-unpleasant-surprise
#12
Vincenzo Vindigni, Eva Kohlscheen, Tajna Kraljic, Franco Bassetto, Chiara Pavan
We present a case of a woman, 79 years old, followed by Psychiatry for depressive episodes after breast cancer removal. She was operated on for ductal breast carcinoma in 1983. Afterward she was submitted to adjuvant radiotherapy. She came to our attention for a chronic skin ulcer that developed into the radio-treated area about 4 years ago. We performed a skin biopsy and programed adipose tissue grafts to promote wound healing. The result of the biopsy was unexpected: dermal localization of not differentiated breast carcinoma...
April 2017: Plastic and Reconstructive Surgery. Global Open
https://www.readbyqxmd.com/read/28507456/adjuvant-intraoperative-radiotherapy-for-selected-breast-cancers-in-previously-irradiated-women-evidence-for-excellent-feasibility-and-favorable-outcomes
#13
Gladys Blandino, Marina Guenzi, Liliana Belgioia, Elisabetta Bonzano, Elena Configliacco, Elena Tornari, Francesca Cavagnetto, Davide Bosetti, Alessandra Fozza, Daniele Friedman, Renzo Corvò
BACKGROUND: The present report provides preliminary outcomes with intraoperative radiotherapy delivered to women with breast cancer included in a re-irradiation program. MATERIALS AND METHODS: From October 2010 to April 2014, thirty women were included in a re-irradiation protocol by exploiting IORT technique. The median time between the two irradiations was 10 years (range 3-50). All patients underwent conservative surgery, sentinel lymph node excision and IORT with electron beam delivered by a mobile linear accelerator...
July 2017: Reports of Practical Oncology and Radiotherapy
https://www.readbyqxmd.com/read/28501763/optimal-duration-of-adjuvant-chemotherapy-for-high-risk-node-negative-n-breast-cancer-patients-6-year-results-of-the-prospective-randomised-multicentre-phase-iii-unicancer-pacs-05-trial-ucbg-0106
#14
Pierre Kerbrat, Isabelle Desmoulins, Lise Roca, Christelle Levy, Alain Lortholary, Alain Marre, Rémy Delva, Maria Rios, Patrice Viens, Étienne Brain, Daniel Serin, Magali Edel, Marc Debled, Mario Campone, Marie-Ange Mourret-Reynier, Thomas Bachelot, Marie-Josèphe Foucher-Goudier, Bernard Asselain, Jérôme Lemonnier, Anne-Laure Martin, Henri Roché
PURPOSE: Optimal duration of adjuvant chemotherapy in the treatment of early-stage breast cancer remained to be investigated rigorously for the standard regimens in widespread use in North America (doxorubicin/cyclophosphamide, AC) and Europe (5-fluorouracil/epirubicin/cyclophosphamide, FEC). Whether six cycles of FEC 100 present an advantage, or not, compared with only four cycles was tested directly in a phase III prospective multicentre trial. PATIENTS AND METHODS: Between 2002 and 2006, 1515 women between 18 and 65°years of age, with node negative N(-) high-risk early-stage breast cancer, were included in the study following breast surgery and axillary lymph node dissection or procedure by sentinel node technique...
May 11, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28500839/evaluating-the-efficacy-of-post-surgery-adjuvant-therapies-used-for-ductal-carcinoma-in-situ-patients-a-network-meta-analysis
#15
Li Wang, Yaoxiong Xia, Dequan Liu, Yueqin Zeng, Li Chang, Lan Li, Yu Hou, Lv Ge, Wenhui Li, Zhijie Liu
OBJECTIVE: Post-surgery adjuvant therapies are very important for patients suffering from ductal carcinoma in situ (DCIS). In this study we conducted a network meta-analysis (NMA) to evaluate the efficacy of different post-surgery adjuvant therapies including tamoxifen, anastrozole and radiation therapy (RT) and their combinations (RT+ tamoxifen and RT+ anastrozole). METHODS: We searched several databases, including Embase, MEDLINE / PUBMED, Cochrane Library, and Science Citation Index, for relevant studies...
April 21, 2017: Oncotarget
https://www.readbyqxmd.com/read/28499277/ppars-as-determinants-of-the-estrogen-receptor-lineage-use-of-synthetic-lethality-for-the-treatment-of-estrogen-receptor-negative-breast-cancer
#16
Robert I Glazer, Levy Kopelovich
The Dilemma: Estrogen receptora-negative (ER-) breast cancer lacks a specific critical target to control tumor progression. THE OBJECTIVE: To identify mechanisms that enable increased expression of the ER+ lineage in an otherwise ER- breast cancer.Preface: The nuclear receptor superfamily members PPARγ and PPARδ regulate gene expression associated with a multitude of pathways, including intermediary metabolism, angiogenesis, proliferation and inflammation (see reviews [1-3]). Recent developments using transgenic and knockout mice, as well as pharmacologic intervention with PPARγ and PPARδ agonists, have revealed a previously unknown relationship between PPARγ suppression and PPARδ activation that leads to the appearance of ER+ tumors, enabling a synthetic lethality approach by anti-ER therapy...
April 20, 2017: Oncotarget
https://www.readbyqxmd.com/read/28498438/dexamethasone-reduces-side-population-fraction-through-downregulation-of-abcg2-transporter-in-mcf-7-breast-cancer-cells
#17
Jong Bin Kim, Sung Eun Hwang, Sang-Pil Yoon
Side population (SP) cells represent a rare population among breast cancer cells. SP cells have been reported to act as cancer stem‑like cells, and to participate in the development of multidrug resistance via modulating the expression of ATP-binding cassette subfamily G member 2 (ABCG2). Dexamethasone is a corticosteroid drug that has been used as an adjuvant treatment to enhance the efficacy of chemotherapeutic agents; however, its effects in breast cancer have yet to be thoroughly investigated. In the present study, the effects of dexamethasone were investigated using the human MCF‑7 breast cancer cell line, and SPs were examined in detail...
May 10, 2017: Molecular Medicine Reports
https://www.readbyqxmd.com/read/28494406/relative-dose-intensity-as-a-proxy-measure-of-quality-and-prognosis-in-adjuvant-chemotherapy-for-breast-cancer-in-daily-clinical-practice
#18
S J Schraa, K A Frerichs, M J Agterof, J C B Hunting, M Los, P C de Jong
AIM: Adjuvant chemotherapy treatment of women with breast cancer is frequently complicated by toxic side-effects, resulting in dose reduction and delay. In Dutch guidelines, a relative dose intensity (RDI) of at least 85% is recommended for optimal treatment. The aim was to investigate predictors of low RDI and its effect on prognosis. METHODS: All patients treated in the St. Antonius Hospital with adjuvant chemotherapy for breast cancer between 2008 and 2013 were included (N = 605)...
May 8, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28494403/her2-status-predicts-for-upfront-ai-benefit-a%C3%A2-trans-aiog-meta-analysis-of-12-129-patients-from%C3%A2-atac-big-1-98-and-team-with-centrally-determined-her2
#19
John M S Bartlett, Ikhlaaq Ahmed, Meredith M Regan, Ivana Sestak, Elizabeth A Mallon, Patrizia Dell'Orto, Beat Thürlimann, Caroline Seynaeve, Hein Putter, Cornelis J H Van de Velde, Cassandra L Brookes, John F Forbes, Giuseppe Viale, Jack Cuzick, Mitchell Dowsett, Daniel W Rea
BACKGROUND: A meta-analysis of the effects of HER2 status, specifically within the first 2-3 years of adjuvant endocrine therapy, has the potential to inform patient selection for upfront aromatase inhibitor (AI) therapy or switching strategy tamoxifen followed by AI. The pre-existing standardisation of methodology for HER2 (immunohistochemistry/fluorescence in situ hybridization) facilitates analysis of existing data for this key marker. METHODS: Following a prospectively designed statistical analysis plan, patient data from 3 phase III trials Arimidex, Tamoxifen, Alone or in Combination Trial (ATAC), Breast International Group (BIG) 1-98 and Tamoxifen Exemestane Adjuvant Multicentre Trial (TEAM)] comparing an AI to tamoxifen during the first 2-3 years of adjuvant endocrine treatment were collected and a treatment-by-marker analysis of distant recurrence-free interval-censored at 2-3 years treatment - for HER2 status × AI versus tamoxifen treatment was performed to address the clinical question relating to efficacy of 'upfront' versus 'switch' strategies for AIs...
May 8, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28493045/impact-of-treatment-regimen-on-acute-care-use-during-and-after-adjuvant-chemotherapy-for-early-stage-breast-cancer
#20
REVIEW
Kathryn J Ruddy, Holly K Van Houten, Lindsey R Sangaralingham, Rachel A Freedman, Carrie A Thompson, Shahrukh K Hashmi, Ahmedin Jemal, Tufia C Haddad, Sarah Mougalian, Jeph Herrin, Cary Gross, Nilay Shah
PURPOSE: The Oncology Care Model was developed, in part, to reduce acute care use during the 6 months after chemotherapy initiation. However, little is known about the impact of chemotherapy regimen on acute care needs, or about later acute care. We sought to assess acute care use over 2 years in patients receiving four contemporary adjuvant chemotherapy regimens for breast cancer. METHODS: Administrative claims data from a large U.S. commercial insurance database (OptumLabs Data Warehouse) were used to retrospectively identify women with early-stage breast cancer who received adjuvant doxorubicin-cyclophosphamide (AC), AC followed or preceded by docetaxel or paclitaxel (AC-T), AC concurrent with docetaxel or paclitaxel (TAC), or docetaxel-cyclophosphamide (TC) between 2008 and 2014...
May 10, 2017: Breast Cancer Research and Treatment
keyword
keyword
116441
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"